Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) traded down 1.5% during trading on Wednesday. The company traded as low as $28.00 and last traded at $28.0560. 37,233,295 shares changed hands during mid-day trading, a decline of 6% from the average session volume of 39,704,832 shares. The stock had previously closed at $28.47.
Latest Pfizer News
Investors following PFE have been watching these news items:
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on PFE shares. Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday. Scotiabank lifted their price target on shares of Pfizer from $33.00 to $35.00 and gave the company a "sector outperform" rating in a research note on Wednesday, November 4th. UBS Group boosted their price target on shares of Pfizer from $27.00 to $30.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 4th. JPMorgan Chase & Co. increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research note on Friday, October 9th. Finally, FBN Securities set a $34.00 price objective on Pfizer in a report on Friday, November 6th. Six research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $30.32.
View Our Latest Report on PFE
Pfizer Trading Down 1.5%
The company has a market cap of $159.91 billion, a P/E ratio of 40.08, a PEG ratio of 1.90 and a beta of 0.31. The company has a current ratio of 1.42, a quick ratio of 1.10 and a debt-to-equity ratio of 0.67. The business has a 50 day moving average price of $28.82 and a 200-day moving average price of $27.01.
Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.13. The business had revenue of $16.58 billion during the quarter, compared to analysts' expectations of $15.85 billion. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The firm's revenue was down .4% on a year-over-year basis. During the same period last year, the business earned $0.87 earnings per share. Analysts forecast that Pfizer Inc. will post 3.04 earnings per share for the current fiscal year.
Pfizer Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer's dividend payout ratio (DPR) is 245.71%.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of PFE. BlackRock Inc. grew its position in Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock worth $12,754,464,000 after buying an additional 31,412,883 shares in the last quarter. State Street Corp increased its stake in Pfizer by 1.8% in the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company's stock worth $7,394,749,000 after acquiring an additional 5,501,032 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Pfizer by 7.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company's stock valued at $1,393,739,000 after acquiring an additional 3,999,646 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Pfizer in the 2nd quarter valued at about $1,049,602,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Pfizer by 4.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 36,157,306 shares of the biopharmaceutical company's stock valued at $870,668,000 after acquiring an additional 1,634,374 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.
About Pfizer
(
Get Free Report)
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company's products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.